Portfolio Receipts of $736 million in Q4 2023 and$3,049 million for FY 2023 Net cash provided by operating activities of $773 million in Q4 2023 and$2,988 million for FY 2023 Announced transactions of up to $4.0 billion in 2023 Full year 2024 guidance: Portfolio Receipts of$2,600 to $2,700 million (reflecting royalty receipts growth of 5% to 9% year/year) excluding future transactions NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the fou ...